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Vaccines can be extremely cost-effective public health measures. Unfortunately the
research and development (R&D) of novel vaccines is suffering from rising costs and
declining success rates. Because many vaccines target low- and middle income
markets (LMIC), output needs to be maintained at a constrained budget. In addition,
scientific neglect and political uncertainty around reimbursement decisions make it an
unattractive arena for private investors. The vaccine development pipeline for LMIC
thus is in need for a different, sustainable, and cost-effective development model. In
conventional vaccine development, objectives for every clinical development phase have
been predefined. However, given the scarcity of resources, the most efficient clinical
development path should identify vaccine candidates with the highest potential impact
as soon as possible. We argue for a custom-made question-based development path
based on the scientific questions, success probabilities and investments required. One
question can be addressed by several studies and one study can provide partial answers
to multiple questions. An example of a question-based approach is the implementation
of a controlled human malaria infection model (CHMI). Malaria vaccine R&D faces major
scientific challenges and has limited resources. Therefore, early preliminary efficacy data
needs to be obtained in order to reallocate resources as efficiently as possible and
reduce clinical development costs. To meet this demand, novel malaria vaccines are
tested for efficacy in so-called CHMI trials in which small groups of healthy volunteers
are vaccinated and subsequently infected with malaria. Early evaluation studies of critical
questions, such as CHMI, are highly rewarding, since they prevent expenditures on
projects that are unlikely to succeed. Each set of estimated probabilities and costs
(combined with market value) will have its own optimal priority sequence of questions to
address. Algorithms can be designed to determine the optimal order in which questions
should be addressed. Experimental infections of healthy volunteers is an example of how
a question-based approach to vaccine development can be implemented and has the
potential to change the arena of clinical vaccine development.
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INTRODUCTION
Vaccines are one of the world’s most important and cost-effective
public health measures and have proven to generate vast socio-
economic benefits (1). The elimination of smallpox and the near-
elimination of polio as a consequence of global use of vaccines
demonstrates the potential impact of these pharmaceuticals.
As such, prophylactic vaccines have a unique niche in the
pharmaceutical industry. Unfortunately, the rising development
costs needed to maintain a constant output of new drugs over
the past decades has affected the vaccine portfolio of major
pharmaceutical companies.
Initially, investors perceived vaccine development to be riskier
than other products, but this view has changed over the past
years (2). Unfortunately, the overall probability of success of
around 11% is not unlike any other pharmaceutical agent (2).
Because the development of new vaccines is often complex,
average development timelines are between 8 and 18.5 years, and
estimated costs are substantial ($200 million to $900 million)
(3, 4). Remarkable examples in this respect are the accelerated
development of an Ebola vaccine and the long timelines in the
development of an HIV vaccine. The risk of failure is particularly
high in later stages of clinical development when vaccines
are tested for their immunogenicity and protective efficacy in
larger (target) populations (2, 4). Given the fierce competition,
the fact that so-called “low-hanging fruits” have been picked,
and in the aftermath of the global financial crisis, the vaccine
development pipeline seems to encounter greater challenges than
ever before (3).
CHALLENGES ASSOCIATED WITH
VACCINES FOR LOW- AND
MIDDLE-INCOME MARKETS
Because the global viral, bacterial, and parasitic infectious disease
burden nowadays is primarily borne by low- and middle- income
countries (LMIC), novel vaccines need to target LMIC markets.
The limited financial capacity of such nations puts constraints
on the vaccine market prices. Advanced scientific technologies
in areas such as immunology, chemistry and molecular biology
have accelerated vaccine development through, for example,
increased understanding of population differences in vaccine
efficacy (3) or identification of correlates of protection (4). While
improving existing vaccines using incremental innovations
can be done relatively fast, the remaining infectious diseases
predominantly prevalent in LMIC require development of a
novel category of vaccines, the foundation of which need to
be laid by fundamental scientists. Whereas governments, non-
governmental organizations and international donors play a
central role in pre-clinical and early clinical development stages
of vaccines, it is likely that private partners are eventually needed
to successfully develop a vaccine for the (LMIC) market.
Predicting vaccine demand in the LMIC countries is
difficult because the infrastructure needed to provide necessary
epidemiological data and information on immunization coverage
and wastage is sometimes lacking. In addition, vaccine uptake
in the Global Alliance for Vaccines and Immunization (GAVI)-
eligible countries may lag behind demand forecasts (3). The
political uncertainty in reimbursement decisions and the public
pressure to reduce prices limits the enthusiasm for private
investors to enter this arena. The current procurement systems
and strong downward price pressures further increase the
uncertainty of recovering costs of development and goods (5).
Lastly, differential pricing, despite its proven public health
success, has been jeopardized by so-called “external price
referencing,” whereby high-income countries seek to benefit from
the lower prices offered to countries with weaker economic
profiles (3).
Given the current vaccine development landscape, the
market-driven business model will need to be revisited in order
to provide a feasible, sustainable, and cost- effective structure for
a global population.
IMPROVING THE BUSINESS CASE FOR
VACCINE DEVELOPMENT
Global recognition of the challenges in vaccine development for
LMIC has increased the support of donors for vaccine research,
particularly from the Bill and Melinda Gates Foundation (6).
These and other direct grants and investment in product
development partnerships (PDPs) have enabled a more active
participation of public partners later in the clinical development
pipeline. Public investments reduce R&D costs and improve
the business case for private partners. Developing country
manufacturers have been able to reduce the production
costs of several vaccines, substantially increasing vaccine cost-
effectiveness and ultimately the population reached. However,
the involvement of large pharmaceutical companies, including
developing country manufacturers, is substantially higher at later
stages of clinical development, reflecting the preference of private
investors for lower risk development. Forty percent (40%) of the
R&D efforts currently invested in neglected diseases is conducted
through product development partnerships (PDPs) (3). However,
also public donors increasingly demand success given hundreds
of vaccine candidates in development globally (7). Considering
the resource constraints, there is a growing need to rationally
identify the approaches that are most likely to succeed and then
prioritize among these candidates (8).
Alternatively, market-based “pull” mechanisms—where
donors stimulate demand for new technologies through
purchase commitments and volume guarantees—incentivize
vaccine research and development by fuelling the business case
from the revenue side. Similarly, effort is put into defining target
product profiles for new vaccines early in the development
process, aiming to reduce risks of late failures by being explicit
about the requirements for novel category vaccines (5). However,
“pull” mechanisms work best when the concept of a new vaccine
is proven and the intrinsic development risks are reduced to
acceptable, technical risks (3).
In conclusion, managing costs and risks of vaccines for
LMIC is challenging. Providing early proof-of-concept of
these vaccines is essential in order to prioritize and ensure
Frontiers in Medicine | www.frontiersin.org 2 October 2018 | Volume 5 | Article 297
Roestenberg et al. Dealing With Uncertainty in Vaccine Development
donor enthusiasm, raise funds from private investors or fuel
collaborations with companies. Obviously, any product will
have intrinsic development risks which are technical in nature.
However, additional uncertainty may be introduced by the lack
of scientific insights which need to be valued within the vaccine
portfolio. Unfortunately, investment decisions on R&D projects
in life sciences are frequently based on Net Present Value (NPV)
calculations that depend heavily on assumptions of technical
risks, costs and future profits while scientific considerations
are not taken into account. NPV analysis just indicates that
such evaluation studies cost time and money and disregards
the increases in knowledge which is obtained when scientific
questions are adequately addressed. Particularly in vaccine
development for LMIC scientific advances are fundamental to
game-changing novel technologies.
QUESTION BASED CLINICAL VACCINE
DEVELOPMENT
Classically, the clinical development program of a vaccine is
divided in four phases:
• Phase 1: Research using small groups of healthy volunteers.
Traditionally, this phase mainly focuses on vaccine safety,
may explore its immunogenicity, and targets to finding a dose
where the level of tolerance is acceptable. In general, this phase
takes about 1–2 years.
• Phase 2: Clinical trials are larger and the first proof for
immunogenicity is established. More characteristics of the
vaccine are determined and a safe and well-tolerated dose is
determined where the drug is immunogenic.
• Phase 3: The potential new vaccine is tested on thousands
of patients in an endemic setting to investigate its safety in
more detail. Furthermore, the efficacy of the vaccine at the
determined dose is determined. Further research is conducted
to investigate possible side effects after long-term treatment
and development of the drug for different indications is
investigated.
• Phase 4: The registered and introduced vaccine is monitored
closely to examine the occurrence of unexpected side-effects
and interactions with other vaccines.
The description of these phases is typically process oriented and
contains very little information about which scientific aspects are
actually covered during the clinical development. Alternatively,
the clinical vaccine development pipeline can be centered around
key scientific questions which need to be addressed in the most
optimal order applicable to the individual investigational vaccine
(Figure 1). Examples of such questions are:
• Does the vaccine formulation induce an immune response
(“Immunogenicity”)?
This main generic question contains several issues that need to
be addressed such as the route and site of vaccine administration.
Not only the immunogenicity of the vaccine antigen, but also
any possible adjuvants, vectors or conjugates could be included
in answering this question.
• Does the vaccine formulation induce a disease correlate of
protection (“Disease correlate”)?
Answering this question includes the demonstration of the
immunological mechanism of action for the investigational
vaccine. As stated previously, R&D investments into mechanisms
of disease and correlates of protection are essential to help answer
this question and as such the associated development risks in
this area may vary considerably. Addressing this question may
be very instrumental in addressing the other questions also. In
diseases where a correlate of protection is lacking, e.g., malaria
or HIV, protective efficacy trials bear substantial risks which have
impeded vaccine development.
• Does the vaccine formulation confer protective efficacy to the
target disease (“Protective efficacy”)?
This question reflects the need to establish beneficial effects on
the incidence or prevalence disease but also the alteration of other
physiological systems resulting in clinical side effects. Depending
on the infection incidence, these trials can be particularly large
in vaccine development in order to achieve sufficient power to
detect efficacy.
• What is the lowest dose and number of doses at which the
vaccine which still induces protective immunity (“Therapeutic
window”)?
The therapeutic window of each investigational vaccine needs
to be established in order to select the optimal dose that
is clinically optimally efficacious at well tolerated levels. This
question includes important sub-questions: how many vaccine
doses need to be given at what interval? Can vaccine formulation
decrease the need for booster doses?
• How do the sources of variability in vaccine response in the
target population affect the development of the product (“Target
population”)?
This question should include: Are there any specific factors in the
target population that may affect immunogenicity? Particularly
in vaccine development for LMIC this can be a significant
hurdle given the generally decreased efficacy of vaccines in
resource-poor settings (9). Co-infections, previous exposure to
the target disease or malnutrition may be factors which hamper
immunogenicity in the target population (10, 11).
The abovementioned questions can be ranked based on their
risk profile and examined in different sequence orders. For
example, if we examine the clinical development path for a
hypothetical malaria vaccine using overall probability of success
of 5%, development costs of 90 eM and revenues of 800
eM. Equal distribution of the risks and costs over the five
proposed questions would amount to a 55% probability of success
and 18 Me costs for each question. The resulting question-
based decision tree (Figure 2A) reflects the true scientific risks
and uncertainties that are faced in the development of an
individual vaccine based on estimations of risks associated with
the postulated questions.
Because it is unlikely that all five questions would contribute
evenly to the overall risks, we now unevenly distribute risks and
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FIGURE 1 | The question optimizing tool, where estimated costs and probabil ities of success can be entered per question, generating a question-based decision
tree with the most optimal order of questions. https://www.pauljanssenfuturelab.eu/our-tools/.
costs in our example (Figure 2B). Despite similar overall costs
and risks, the project value can vary substantially depending on
the distribution of question-associated risks and costs. Similarly,
the order of questions strongly determines the project value
as illustrated by the dramatic drop in project value if the
user-defined “Therapeutic window” is the first question to be
addressed with these input variables. In this case, the overall
project value actually drops below zero, implying that risks and
investments do not outweigh the potential revenues.
Furthermore, the question-based approach illustrates how the
project value can increase by performing an additional early
phase evaluation study that helps to adequately answer a critical
question. If an additional 1 Me costs and a 5% increased
probability of successfully answering the “Disease correlate”
question is added, the overall project value increases by more
than 50% (Figure 2C), despite the fact that the overall probability
of success increases with only 0.17–5.17% and overall costs
increase by 1–91 Me.
By defining the costs and probabilities of success and
constructing the decision tree for every new vaccine, the
bottleneck in the development of each individual vaccine
will be identified. Presumably for most vaccines the “Disease
correlate” and “Protective efficacy” questions will have the
lowest probability of success. As explained earlier, the increasing
recognition of this critical bottleneck in vaccine development has
led to a demand for proof-of-concept clinical trials showing early
efficacy for the candidate vaccine technology. In the next section,
we will take the example of malaria vaccine development to
illustrate how question-based product development has changed
malaria vaccine development and fostered novel technology
development in this field.
THE EXAMPLE OF MALARIA VACCINE
DEVELOPMENT AND THE ROLE OF
CONTROLLED HUMAN MALARIA
INFECTIONS
Despite the fact that half the world’s population is at risk
for malaria with an extremely high global burden of 200
million malaria cases annually and nearly 500,000 deaths
among children, the vast majority of the burden is borne
by resource-poor countries in Sub-Saharan Africa (12). Most
malaria deaths are caused by onemicrobial species: the protozoan
Plasmodium falciparum (Pf). This organism displays extracellular
and intracellular developmental stages and transforms within
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FIGURE 2 | Decision tree showing the optimal order of questions to generate the highest project value, given estimated probability of success (PoS) and costs (million
euro, eM) per scientific question. In the case PoS and costs for every question are equal, the order does not matter for the project value (A), however unequal
distributions will clearly show different project values for the optimal order in blue, second best order in red and user defined order in green (B). A 1 eM additional
investment in “correlates” has a major effect on the optimal order and project value (C).
the human host, creating a challenge for the immune system
and therefore also a scientific challenge for malaria vaccine
development. Because there are no prior registered vaccines for
parasitic diseases, malaria vaccine development cannot draw on
experience from other disease areas. In addition, despite decades
of vaccine research, there are no correlates of protection for
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Pf malaria. Lastly, Pf strains worldwide display considerable
genetic variability which may affect local vaccine efficacy. As
a consequence, the probability of successful market entry for
malaria vaccines is extremely low even after 7–8 years of clinical
development (4) and the investment into malaria vaccines is
extremely small as compared to other disease areas such as
influenza or HIV/AIDS (4). A radical approach to tackle R&D
uncertainty and boost scientific advances is thus urgently needed.
Initially developed as a treatment for neurosyphilis before the
discovery of penicillin, the methods for experimental infection
of volunteers with malaria have been adapted as a tool to serve
the malaria vaccine pipeline (13). The human infection model
was standardized by means of (automated) parasite cultures and
laboratory-bred mosquito colonies (14, 15). Nowadays, both the
blood-stage as well as the mosquito stage of the Pf parasite can be
GMP manufactured and injected for this purpose (16, 17). The
model is known as “controlled humanmalaria infection (CHMI)”
to stress the importance of the standardization and the highly
controlled follow-up which ensures that severe malaria does not
occur and participants are treated as early as possible.
Within the vaccine development pipeline, CHMI has been
increasingly used to address the “Disease correlate” question
in the absence of a known correlate of protection. Despite
the fact that a formal validation was never done, CHMI
trials are nowadays widely accepted as a critical step in
the clinical development path. Using the CHMI model, one
vaccine—GlaxoSmithKline Mosquirix—has received marked
authorization in 2016 following a proof-of-concept clinical trial
more than 10 years earlier (18). An implementation pilot
to evaluate its use in the field is currently ongoing. The
product development partnership “Malaria Vaccine Initiative,”
has very successfully advanced this vaccine for the public sector
and simultaneously managed global access and IP issues with
commercial partners (5). CHMI has also fostered unconventional
approaches to vaccine development such as the live-attenuated
malaria vaccine PfSPZ Vaccine which is entering phase 3 clinical
trials, led by the US biotech company Sanaria (17). Furthermore,
disappointing CHMI results have stopped the development other
candidate malaria vaccines (19).
The CHMI trials are thus a prime example how questions
with the lowest probability of success can be addressed in early
clinical development. Because of their invasive nature and the
requirement for healthy volunteers, which seemingly contradict
the principle of “primumnon nocere,” CHMI trials initially raised
ethical debate but nowadays have gained acceptance through
demonstrating their accelerating scientific potential and the fact
that CHMIs have been safely performed in >3,000 volunteers
worldwide (20).
Following the example of malaria, the experimental infection
of volunteers are also being used as a tool for the development of
novel products in other infectious disease areas such as influenza,
rhinovirus or cholera (21). In exceptional cases, such as the
cholera vaccine VaxChora, this trial was the basis for registration
of a novel vaccine (21). However, the position of CHI trials within
the vaccine development pipeline and their value in mitigating
the development risk is highly dependent on its scientific validity.
Therefore, attention should be paid to the scientific details of the
CHI trial setup, in particular to the proposed vaccine mechanism
of action, the vaccine target population and the position of the
CHI model within the vaccine product pipeline. Specific points
to be considered are outlined below.
RESTRICTIONS AND SOLUTIONS FOR CHI
MODELS
Mechanism of Action
Vaccines consist of one or multiple antigens and as such target
prevention of disease, infection or colonization. Because CHI
trials are often designed as preliminary experiments which only
include a very small group of volunteers, endpoints should be
selected based on their power to discriminate vaccine effects.
Preferably, these trials target a relevant (clinical) endpoint,
addressing a claim in the vaccine target product profile, such
as diarrhea in the case of cholera CHI (22) or fever in
the case of typhoid CHI (23). Alternatively, an intermediate
(microbiological) endpoint may be selected, such as viremia in
the dengue model (24) or parasitemia in the malaria model.
However, for malaria, infection does not always parallel disease
particularly in endemic areas (25). Depending on the target
disease the CHI endpoint as such may be a surrogate to clinical
endpoint and will need to be validated in epidemiological studies
or in later field trials (Table 1).
In addition, the vaccine antigen(s) should be sufficiently
present in the CHI model to measure protective effects. For
example, in the malaria case, a liver-stage malaria vaccine can
be tested for its preliminary efficacy by a mosquito-bite CHMI.
However, for blood stage malaria vaccines, this model is less
suitable because blood stage parasitemia will be limited to only
a very short (3–4 day) timeframe in a mosquito bite CHMI (26).
TABLE 1 | Examples of potential restrictions and solutions for CHI models within
the vaccine product pipeline.
Topic Restriction Solutions
Mechanism of
action
Model endpoint does not
reflect vaccine efficacy
endpoint
Define endpoints to balance
clinical relevance and
feasibility in small groups.
Validation of endpoints in
epidemiological studies.
Challenge strain does not
express vaccine antigen, or
correct strain not available
Design of fit-for-purpose
challenge strains or models
Model validation Model population does not
reflect target population
Transfer of CHI trials to
endemic areas and
susceptible populations
Challenge strain does not
reflect circulating field
strains
Increase portfolio of
challenge strains to reflect
natural infections
Position of CHI in
product
development
pipeline
False negative result in CHI
trial leads to no-go decision
for further development of
potentially valuable product
Clear definition of the
research question which the
model addresses
Acceptance of CHI data in
registration dossiers
Early involvement of
regulators
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Therefore, the CHMI model was adapted to accommodate a
longer phase of blood stage parasitemia. This blood stage CHMI
has the possibility to detect small alterations in blood stage
development of malaria parasites (16).
Model Validation
Generally, CHI trials are performed in healthy adult volunteers
which do not necessarily reflect the target population, which is
typically much more heterogeneous. In order to overcome these
differences, CHI trials can also be performed in more susceptible
(target) populations such as COPD patients for rhinovirus (27)
or malaria infections in Sub-Saharan Africa (28). Interestingly,
controlled human malaria infections in non-endemic high-
income settings have a much higher clinical attack rate and
parasitemia as compared to rural African populations. In the
latter population parasitemia is much more variable, and clinical
disease may be lacking despite parasitemia (25). It is plausible
that this reflects different immunological responses, which may
be unraveled in the future.
Given the invasive nature of the CHI trial, regulatory
authorities will often demand strictly controlled production of
challenge material. In addition to the fact that such processes
may be difficult, expensive and time-consuming, the process
itself may render the challenge material less representative of
microbes circulating in the field. For example, passage of virus
strains through well-characterized cell lines to produce Good
Manufacturing Practice compliant strains, will unequivocally
alter the genetic makeup of the virus. Alternatively, the well-
characterized laboratory strains such as the Quailes strain used
for typhoid CHI (23) or the NF54/3D7 strain for Pf CHI (20)
may not reflect the heterogeneity of field strains which impacts
the scientific value of the model to predict field efficacy.
Position of CHI in the Product
Development Pipeline
Depending on the scientific and clinical details of the CHI model
mentioned above, the CHI model can be used as a tool to answer
one or multiple questions in the product development pipeline.
Determining the most optimal order in which these questions
should be addressed, will aid in positioning the CHI model in
the pipeline. Because CHI models often address high-risk clinical
development questions, they are optimally performed early in
clinical development. Previously, this has led to hesitancy by
vaccine developers, who fear that negative results will result in a
“no-go” decision for a vaccine which may actually be efficacious
in later trials. However, as in any other model, the results of the
model system should be valued for its merits within the scientific
question which it addresses. For example, a CHMI trial may
enable identification of an immunological correlate of protection
in a trial which shows only partial efficacy. The correlate
will de-risk other clinical development questions. Depending
on the outcome of the trial, these need to be reassessed
and risks adjusted to come up with the then optimal order
based on the required investments and updated probability of
success.
Increasing familiarity of CHI models by regulators as well
as vaccine developers increases acceptance of these trials as
part of the regulatory package which is submitted for licensure.
However, given the restrictions of CHI models, continuous
education of regulators, and vaccine developers to increase the
scientific understanding of these models is essential to ensure
that data from these trials are interpreted appropriately. In the
end, regulation follows science, not the other way around. The
malaria example shows how a well-designed CHI trial early in
clinical development can dramatically improve the business case
of the experimental vaccine and ultimately lead to registration of
a LMIC vaccine with global impact.
CONCLUSIONS
In conclusion, global vaccine development faces major
challenges, particularly for LMIC settings. Initiatives to
improve the business case for vaccine development including
so-called “pull” mechanisms to ensure pricing and guarantee
demand are needed but will not provide the ultimate solution.
A question-based clinical development approach can provide
the insights on critical steps in the development path for novel
vaccines and will help display the priorities within the program.
Controlled human infections, if well designed, are an excellent
example of how question based product development has led to
adjustments to the product development pipeline and the way to
prioritize vaccine candidates, accelerate novel vaccines, reallocate
resources and foster novel technologies. During development,
the estimations in the question based approach require constant
evaluation and adjustment in order to keep development on
the optimal path. Ultimately, this approach has the potential to
more quickly improve global health and hopefully increase the
appetite for private investors to enter the arena of clinical vaccine
development and work together with public funders to target
low income markets despite small profit margins. In addition,
it will foster scientific advances which are needed to turn the
tide on the development of vaccines for neglected infections of
global importance, increase enthusiasm for public investments
and the public pressure needed to stimulate societal corporate
responsibility.
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